Eloxx Pharmaceuticals Board Changes
Ticker: ELOX · Form: 8-K · Filed: Mar 29, 2024 · CIK: 1035354
| Field | Detail |
|---|---|
| Company | Eloxx Pharmaceuticals, Inc. (ELOX) |
| Form Type | 8-K |
| Filed Date | Mar 29, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01, $0 |
| Sentiment | neutral |
Sentiment: neutral
Topics: board-change, management
Related Tickers: ELOX
TL;DR
Eloxx Pharma board shakeup: Dr. Smith out, Dr. Micklos in.
AI Summary
Eloxx Pharmaceuticals, Inc. announced on March 25, 2024, a change in its board of directors. Specifically, Dr. Jonathan G. W. Smith has resigned from his position as a director. The company has also appointed Dr. David E. Micklos as a new director, effective immediately.
Why It Matters
Changes in board composition can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: low — The filing reports routine board changes, which typically carry low immediate risk.
Key Players & Entities
- Eloxx Pharmaceuticals, Inc. (company) — Registrant
- Dr. Jonathan G. W. Smith (person) — Resigned Director
- Dr. David E. Micklos (person) — Appointed Director
- March 25, 2024 (date) — Date of earliest event reported
FAQ
Who resigned from the Eloxx Pharmaceuticals board of directors?
Dr. Jonathan G. W. Smith resigned from the board of directors.
When was the earliest event reported in this filing?
The earliest event reported was on March 25, 2024.
Who was appointed to the Eloxx Pharmaceuticals board of directors?
Dr. David E. Micklos was appointed as a new director.
What is the state of incorporation for Eloxx Pharmaceuticals, Inc.?
Eloxx Pharmaceuticals, Inc. is incorporated in Delaware.
What is the business address of Eloxx Pharmaceuticals, Inc.?
The business address is 480 Arsenal Way, Suite 130, Watertown, MA 02472.
Filing Stats: 551 words · 2 min read · ~2 pages · Grade level 12.2 · Accepted 2024-03-29 16:11:23
Key Financial Figures
- $0.01 — e on which registered Common Stock, $0.01 par value per share ELOX The Nasdaq C
- $0 — mended to reduce such exercise price to $0.90, the closing price per share of the
Filing Documents
- tm248887d2_8k.htm (8-K) — 28KB
- 0001104659-24-041148.txt ( ) — 196KB
- elox-20240325.xsd (EX-101.SCH) — 3KB
- elox-20240325_lab.xml (EX-101.LAB) — 33KB
- elox-20240325_pre.xml (EX-101.PRE) — 22KB
- tm248887d2_8k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: March 29, 2024 ELOXX PHARMACEUTICALS, INC. By: /s/ Sumit Aggarwal Name: Sumit Aggarwal Title: President and Chief Executive Officer